Sign in
Taking peopleNo phase

How Soon Ultrasound Signs of Giant Cell Arteritis Fade After Steroid Treatment

Studies how fast artery ultrasound changes disappear after steroids in people with giant cell arteritis.

Key facts

Who runs it
Centre Hospitalier le Mans
Where
France6 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients
Status
Recruiting
People taking part
64 people, planned
Started
27 Feb 2026
Expected to end
Feb 2028
Type of study
Interventional
Treatments tested
  • Doppler Ultrasound
Record updated
17 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 and over with newly diagnosed giant cell arteritis (GCA). They must show a halo sign on Doppler ultrasound of the temporal artery and be about to start corticosteroid treatment.

Age
50 years and over
Sex
All sexes
Disease stage
Newly diagnosed GCA meeting the ACR 2022 classification criteria. A halo sign on one or both sides on Doppler ultrasound of the temporal artery. Corticosteroid treatment is needed.
Earlier treatment
No corticosteroid treatment for GCA yet. No oral corticosteroids in the past month and none now (hydrocortisone or local corticosteroids are allowed). No immunosuppressive treatment or biotherapy in the month before joining.
Biomarker or test result
No ANCA (antibodies against neutrophil cytoplasm), negative syphilis blood test and negative IGRA test.

Main reasons for not taking part

  • GCA that has come back (relapse)
  • A past temporal artery biopsy, for any reason
  • Another type of vasculitis that could explain the symptoms
  • Cannot have corticosteroid treatment
  • Under legal protection or not covered by social security

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients aged 50 and over
  • Without legal protection
  • Meeting GCA classification criteria as defined by ACR 2022 with the presence of a halo sign-unilateral or bilateral-on Doppler ultrasound of the temporal artery
  • Newly diagnosed with an indication for corticosteroid treatment
  • Have not yet received corticosteroid treatment for GCA
  • No contraindication to corticosteroid treatment
  • Person affiliated with or benefiting from a social security scheme
  • Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination necessary for the research)

Who cannot take part

  • Patients who have previously undergone a temporal artery biopsy (TAB), including for other reasons
  • Patients who have received oral corticosteroid treatment in the past month or are currently on corticosteroid therapy (excluding hydrocortisone or local corticosteroids)
  • Patients having received immunosuppressive treatment or biotherapy in the month prior to inclusion. If the patient's condition warrants the use of biotherapy or immunosuppressive treatment, its initiation will be delayed until after Day 7 to avoid interfering with the Doppler procedure
  • Patients with other types of vasculitis that may constitute a differential diagnosis: presence of antibodies against the cytoplasm of neutrophils (ANCA), positive syphilis serology, positivity of an IGRA test (Interferon Gamma Release Assay)
  • Patients with a relapse of Giant Cell Arteritis (GCA)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50. Vasculitis lesions cause thickening of the arterial wall, visible on temporal artery biopsy (TAB) or vascular imaging (echo-Doppler, angio-CT, angio-MRI, 18FDG PET-CT). This is a severe disease that can lead to blindness. Early diagnosis is essential, so that steroids therapy can be started as soon as possible to prevent complications. Doppler ultrasonography of the temporal arteries provides rapid, non-invasive diagnostic support. However, the recommendations do not specify how soon temporal artery Doppler should be performed after steroids treatment, except that the halo sign would disappear after about 5 days on steroids. Sensitivity seems to be better when the examination is performed early, but the time taken for the halo sign to disappear is unknown. The investigator suggests that the disappearance of the temporal artery halo sign in GCA patients is observed earlier than D14 of steroids treatment usually reported in the literature. He speculates that the sensitivity of the temporal artery Doppler decreases as early as D3 of steroids treatment, and that beyond D7 it is not useful to perform this examination as its sensitivity becomes too low.

The group in the trial

  • Timeframe for Halo sign resolution on Doppler ultrasoundTreatment being tested

    Doppler ultrasound of temporal arteries at D0, D3 and D7 (+/- D15) after initiation of corticosteroid therapy.

    Treatment: Doppler Ultrasound

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients
Plain-language title
How Soon Ultrasound Signs of Giant Cell Arteritis Fade After Steroid TreatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
17 July 2026